Phase I of Vorinostat-Iressa combined therapy on resistance by BIM polymorphysim in EGFR Mutant Lung Cancer - VICTORY-J(Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer-JAPAN)

Cancer Research Center, Kanazawa University0 个研究点目标入组 18 人开始时间: 2014年9月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Within 4 weeks after the final administration of a cytotoxic anticancer agent.Allowable enrollment when a 7-day washout is completed after the final administration of an EGFR-TKI. Surgery of a primary tumor or to the mediastinum must be completed at least 6 months before the onset of protocol treatment. Radiotherapy to the lungs considered necessary at the time of study entry or in the near future. Having an interstitial lung disease (including acute pulmonary disorder, interstitial pneumonia, and drug inducibility) or having a history thereof. Having radiation pneumonitis or having a history thereof. Having a large volume of or uncontrollable pleural effusion, ascites, or pericardial effusion Detection of known EGFR-TKI resistance acquired by mutations of the genes, e.g., T790M. Suffering from a severe or poorly controlled systemic disease (e.g., unstable or decompensated respiratory disease, heart disease, renal disease, and liver disease)

发起方

Cancer Research Center, Kanazawa University